Δημοσιεύσεις 2015

PROGNOSTIC AND PREDICTIVE ROLE OF VASCULAR ENDOTHELIAL GROWTH FACTOR POLYMORPHISMS IN BREAST CANCER

Koutras A, Kotoula V, Fountzilas G.

Pharmacogenomics. 2015 Jan;16(1):79-94. doi: 10.2217/pgs.14.148

IMPACT OF TUMOR ANGIOGENIC PROFILE ON THE OUTCOME OF PATIENTS WITH METASTATIC BREAST CARCINOMA TREATED WITH WEEKLY DOCETAXEL. A HELLENIC COOPERATIVE ONCOLOGY GROUP (HECOG) STUDY

H.P. Kourea, V. Kotoula, A. Koutras, Z. Alexopoulou, I. Papaspirou, D.V. Skarlos, I. Efstratiou, M. Bobos, F. Zagouri, P. Papakostas, D. Pectasides, S. Chrisafi, I. Varthalitis, G. Aravantinos, P. Kosmidis, D. Bafaloukos, C.D. Scopa and G. Fountzilas

Histol Histopathol (2015) 30: 1129-1141

EVALUATION OF TWO HIGHLY-MULTIPLEXED CUSTOM PANELS FOR MASSIVELY PARALLEL SEMICONDUCTOR SEQUENCING ON PARAFFIN DNA

V. Kotoula, A. Lyberopoulou, K. Papadopoulou, E. Charalambous, Z. Alexopoulou, C. Gakou, S. Lakis, E. Tsolaki, K. Lilakos, G. Fountzilas

PLoS One. 2015 Jun 3;10(6):e0128818. doi: 10.1371/journal.pone.0128818.

PAI-1 AND HER2 INTERACTION IN METASTATIC BREAST CANCER DISEASE: EVIDENCE FOR ADDED BENEFIT FROM TRASTUZUMAB IN HER2-NEGATIVE PATIENTS

A. Koumarianou, G. Karayannopoulou, G. Gourgioti, A. Batistatou, M. Bobos, I. Efstratiou, D. Miliaras, E. Galani, G. Pentheroudakis, D. Pectasides, G. Aravantinos, D. Bafaloukos, P. Papakostas, E. Razis, H. P. Kalofonos, Kalliopi Petraki, Maria Sotiropoulou, Konstantine T. Kalogeras, George Fountzilas

Cancer Chemother Pharmacol. 2015 Jun;75(6):1289-301. doi: 10.1007/s00280-015-2762-3.

CHEK2 c.1100delC ALLELE IS RARELY IDENTIFIED IN GREEK BREAST CANCER CASES

P. Apostolou, F. Fostira, M. Papamentzelopoulou, M. Michelli, C. Panopoulos, G. Fountzilas, I. Konstantopoulou, G.E Voutsinas, D. Yannoukakos

Cancer Genet. 2015 Apr;208(4):129-34. doi: 10.1016/j.cancergen.2015.02.006.

p85 PROTEIN EXPRESSION IS ASSOCIATED WITH POOR SURVIVAL IN HER2-POSITIVE PATIENTS WITH ADVANCED BREAST CANCER TREATED WITH TRASTUZUMAB

K. Pavlakis, M. Bobos, A. Batistatou, V. Kotoula, A.G Eleftheraki, A. Stofas, E. Timotheadou, G. Pentheroudakis, A. Psyrri, A. Koutras, D. Pectasides, P. Papakostas, E. Razis, C. Christodoulou, K.T Kalogeras, G. Fountzilas

Pathol Oncol Res. 2015 Apr;21(2):273-82. doi: 10.1007/s12253-014-9818-2.

SIGNIFICANCE OF THE TYPE OF PIK3CA MUTATIONS IN PATIENTS WITH EARLY BREAST CANCER TREATED WITH ADJUVANT CHEMOTHERAPY: A Hellenic Cooperative Oncology Group (HeCOG) study

G.Papaxoinis, V. Kotoula, Z. Alexopoulou, K.T. Kalogeras, F. Zagouri, E. Timotheadou, H. Gogas, G. Pentheroudakis, Ch. Christodoulou, A. Koutras, D. Bafaloukos, G. Aravantinos, P. Papakostas, E. Charalambous, K. Papadopoulou, I. Varthalitis, I. Efstratiou, Th. Zaramboukas, H. Patsea, C. D. Scopa, M. Skondra, P. Kosmidis, D. Pectasides, G. Fountzilas 

PLoS One. 2015 Oct 9;10(10):e0140293. doi: 10.1371/journal.pone.0140293.

TUMORS WITH HIGH-DENSITY TUMOR INFILTRATING LYMPHOCYTES CONSTITUTE A FAVORABLE ENTITY IN BREAST CANCER: A POOLED ANALYSIS OF FOUR PROSPECTIVE ADJUVANT TRIALS

V. Kotoula, K. Chatzopoulos, S. Lakis, Z. Alexopoulou, E. Timotheadou, F. Zagouri, G. Pentheroudakis, H. Gogas, E. Galani, I. Efstratiou, Th. Zaramboukas, A. Koutras, G. Aravantinos, E. Samantas, A. Psyrri, H. Kourea, M. Bobos, P. Papakostas, P. Kosmidis, D. Pectasides, G. Fountzilas

Oncotarget. 2015 Oct 25. doi: 10.18632/oncotarget.6231.

PREDICTIVE BIOMARKERS TO CHEMOTHERAPY IN PATIENTS WITH ADVANCED MELANOMA RECEIVING THE COMBINATION OF CISPLATIN-VINBLASTINE-TEMOZOLOMIDE (PVT) AS FIRST-LINE TREATMENT: A STUDY OF THE HELLENIC COOPERATIVE ONCOLOGY GROUP (HeCOG)

H. Linardou, G. Pentheroudakis, I. Varthalitis, H. Gogas, D. Pectasides, T. Makatsoris, G. Fountzilas, D. Bafaloukos

Anticancer Res. 2015 Feb;35(2):1105-13

IMMUNE RESPONSE GENE EXPRESSION IN COLORECTAL CANCER CARRIES DISTINCT PROGNOSTIC IMPLICATIONS ACCORDING TO TISSUE, STAGE AND SITE: A PROSPECTIVE RETROSPECTIVE TRANSLATIONAL STUDY IN THE CONTEXT OF A HELLENIC COOPERATIVE ONCOLOGY GROUP RANDOMISED TRIAL

Pentheroudakis G, Raptou G, Kotoula V, Wirtz RM, Vrettou E, Karavasilis V, Gourgioti G, Gakou C, Syrigos KN, Bournakis E, Rallis G, Varthalitis I, Galani E, Lazaridis G, Papaxoinis G, Pectasides D, Aravantinos G, Makatsoris T, Kalogeras KT, Fountzilas G.

PLoS One. 2015 May 13;10(5):e0124612. doi: 10.1371/journal.pone.0124612.

RANDOMIZED PHASE III CLINICAL TRIAL COMPARING THE COMBINATION OF CAPECITABINE AND OXALIPLATIN (CAPOX) WITH THE COMBINATION OF 5-FLUOROURACIL, LEUCOVORIN AND OXALIPLATIN (MODIFIED FOLFOX6) AS ADJUVANT THERAPY IN PATIENTS WITH OPERATED HIGH-RISK STAGE II OR STAGE III COLORECTAL CANCER

D. Pectasides, V. Karavasilis, G. Papaxoinis, G. Gourgioti, T. Makatsoris, G. Raptou, E. Vrettou, J. Sgouros, E. Samantas, G. Basdanis, P. Papakostas, D. Bafaloukos, V. Kotoula, H.P Kalofonos, C.D Scopa, G. Pentheroudakis, G. Fountzilas

BMC Cancer. 2015 May 10;15:384. doi: 10.1186/s12885-015-1406-7.

INTACT OR BROKEN-APART RNA: AN ALTERNATIVE CONCEPT FOR ALK FUSION SCREENING IN NON-SMALL CELL LUNG CANCER (NSCLC)

V. Kotoula, M. Bobos, M. Vassilakopoulou, E. Tsolaki, S. Chrisafi, A. Psyrri, G. Lazaridis, K. Papadopoulou, I. Efstratiou, C. Michail-Strantzia, L.V Debelenko, P. Kosmidis, G. Fountzilas

Appl Immunohistochem Mol Morphol. 2015 Jan;23(1):60-70. doi: 10.1097/PAI.0000000000000028.